Results 31 to 40 of about 2,266 (198)

Two-Year Real-World Results for Aflibercept Using the Treat-and-Extend Regimen in Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy

Ophthalmology and Therapy, 2023
Introduction To evaluate the real-world efficacy of aflibercept using the treat-and-extend (TnE) regimen in treating neovascular age-related macular degeneration (nAMD) and polypoidal choroidal vasculopathy (PCV), and to analyze biomarkers using optical ...
Chu-Hsuan Huang, Tso-Ting Lai, Chang-Hao Yang, Yi-Ting Hsieh   +3 more
doaj   +1 more source

Treat and Extend Treatment Interval Patterns with Anti-VEGF Therapy in nAMD Patients

Vision, 2019
Treat and extend (T&E) is a standard treatment regimen for treating neovascular age-related macular degeneration (nAMD) with anti-vascular endothelial growth factors (anti-VEGFs), but the treatment intervals attained are not well documented.
Adrian Skelly, Vladimir Bezlyak, Gerald Liew, Elisabeth Kap, Alexandros Sagkriotis   +4 more
doaj   +1 more source

Recurrence of neovascular age-related macular degeneration after cessation of treat and extend regimen

Scientific Reports, 2022
The appropriate timing of treatment cessation after treat and extend (TAE) regimen for age-related macular degeneration has not been established. This study aimed to investigate the incidence and risk factors of recurrence after cessation of the TAE ...
Yuki Hirata, Akio Oishi, Yuki Maekawa, Eiko Tsuiki, Akira Machida, Junko Kurihara, Takashi Kitaoka   +6 more
doaj   +1 more source

Dendritic cells steering antigen and leukocyte traffic in lymph nodes

FEBS Letters, EarlyView.
Dendritic cells are key players in the activation of T cells and their commitment to effector function. In this In a Nutshell Review, we will discuss how dendritic cells guide the trafficking of antigen and leukocytes in the lymph node, thus influencing T‐cell activation processes. Dendritic cells (DCs) play a central role in initiating and shaping the
Enrico Dotta, Agnieszka Katarzyna Maciola, Tania Baccega, Giulia Pasqual   +3 more
wiley   +1 more source

Treat-and-Extend Versus Pro re nata Regimens of Ranibizumab and Aflibercept in Neovascular Age-Related Macular Degeneration: A Comparative Study from Routine Clinical Practice

Ophthalmology and Therapy
Introduction Anti-vascular endothelial growth factor (VEGF) is generally given using pro re nata or “treat-and-extend” (T&E) regimens for neovascular age-related macular degeneration (nAMD).
Eloi Debourdeau, Helene Beylerian, Vuong Nguyen, Daniel Barthelmes, Mark Gillies, Pierre Henry Gabrielle, Stela Vujosevic, Louise Otoole, Martin Puzo, Catherine Creuzot-Garcher, Benjamin Wolff, Vincent Daien, The Fight Retinal Blindness! Study Group   +12 more
doaj   +1 more source

FoxO1 signaling in B cell malignancies and its therapeutic targeting

FEBS Letters, EarlyView.
FoxO1 has context‐specific tumor suppressor or oncogenic character in myeloid and B cell malignancies. This includes tumor‐promoting properties such as stemness maintenance and DNA damage tolerance in acute leukemias, or regulation of cell proliferation and survival, or migration in mature B cell malignancies.
Krystof Hlavac, Petra Pavelkova, Laura Ondrisova, Marek Mraz   +3 more
wiley   +1 more source

Clinical Outcomes of a Treat and Extend Regimen with Intravitreal Aflibercept Injections in Patients with Diabetic Macular Edema: Experience in Clinical Practice

Ophthalmology and Therapy, 2019
Introduction Treat-and-extend (T&E) and pro re nata (PRN; ‘as needed’) regimens of intravitreal anti-vascular endothelial growth factor (VEGF) treatment have been found to reduce the injection burden on patients and improve the cost effectiveness of the ...
Beverley A. Curry, Paul G. Sanfilippo, Sarah Chan, Alexander W. Hewitt, Nitin Verma   +4 more
doaj   +1 more source

Insights into PI3K/AKT signaling in B cell development and chronic lymphocytic leukemia

FEBS Letters, EarlyView.
This Review explores how the phosphoinositide 3‐kinase and protein kinase B pathway shapes B cell development and drives chronic lymphocytic leukemia, a common blood cancer. It examines how signaling levels affect disease progression, addresses treatment challenges, and introduces novel experimental strategies to improve therapies and patient outcomes.
Maike Buchner
wiley   +1 more source

Functional variation among LPMOs revealed by the inhibitory effects of cyanide and buffer ions

FEBS Letters, EarlyView.
This study addresses the inhibition of lytic polysaccharide monooxygenases (LPMOs) by cyanide and explains how and why the magnitude of observed inhibitory effects depends on the way LPMO reactions are setup and on the type of LPMO. Enzymes known as lytic polysaccharide monooxygenases (LPMOs) are mono‐copper polysaccharide‐degrading peroxygenases that ...
Ole Golten, Lorenz Schwaiger, Zarah Forsberg, Kelsi R. Hall, Anton A. Stepnov, Tom Z. Emrich‐Mills, Iván Ayuso‐Fernández, Morten Sørlie, Roland Ludwig, Åsmund Kjendseth Røhr, Vincent G. H. Eijsink   +10 more
wiley   +1 more source

Structural and mechanistic basis for the regulation of the chloroplast signal recognition particle by (p)ppGpp

FEBS Letters, EarlyView.
LHCPs are transported to the thylakoid membrane via the (cp)SRP pathway. This process involves a transit complex of (cp)SRP43, (cp)SRP54 and LHCP, which interacts with (cp)FtsY and Alb3 at the membrane. GTP hydrolysis by (cp)SRP54 and (cp)FtsY triggers complex dissociation.
Victor Zegarra, Paul Weiland, Pauline Anka Plitzko, Julia Thiery, Laura Czech, Felix Willmund, Patricia Bedrunka, Gert Bange   +7 more
wiley   +1 more source